세계의 흡입약 시장 : 약제 클래스별, 제품 유형별, 용도별, 유통 채널별, 지역별
Global Inhalable Drugs Market, By Drug Class (Inhaled Corticosteroids, Leukotriene modifiers, Long-acting beta agonists, Long-acting muscarinic antagonists, Others), By Product Type, By Application, By Distribution Channel, By Region
상품코드
:
1424371
리서치사
:
Coherent Market Insights
발행일
:
2023년 12월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 흡입약 시장 규모는 2023년 348억 6,000만 달러에서 2030년에는 566억 8,000만 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR은 7.2%를 나타냅니다.
| 리포트 범위 |
리포트 상세 |
| 기준년 |
2022년 |
2023/2024년 시장 규모 |
348억 6,000만 달러 |
| 실적 데이터 |
2018-2021년 |
예측 기간 |
2023-2030년 |
| 예측 기간 2023년/2024-2030년/2031년 CAGR |
7.20% |
2030/2031년 가치 예측 |
566억 8,000만 달러 |
도표 1. 세계의 흡입약 시장 점유율(%), 지역별, 2023년
흡입 가능한 의약품은 폐를 통해 호흡기를 통해 국소적으로 투여하여 빠른 치료 효과를 나타내는 의료용 물질입니다. 천식, 만성폐쇄성폐질환, 낭포성 섬유증 등 폐질환 치료에 특히 효과적입니다. 폐는 소화관을 통한 경구 투여에 비해 약물 흡수를 위한 거대한 표면적을 제공합니다. 흡입 가능한 약물은 간 1차 통과 대사를 우회하여 폐 조직에 직접 약물을 신속하게 전달하여 전신 수준을 낮출 수 있습니다. 주요 장점은 경구용 약물에 비해 몇 분 이내에 빠른 약효 발현, 저용량 투여, 부작용 감소 등을 들 수 있습니다. 인기 있는 흡입제에는 알부테롤과 같은 천식 및 만성폐쇄성폐질환용 기관지확장제, 코르티코스테로이드, 분 산성 항생제, 인슐린 등이 있습니다. 전 세계에서 폐질환이 증가함에 따라 흡입형 의약품 시장은 앞으로도 안정적인 성장이 예상됩니다.
시장 역학:.
세계 흡입제 시장은 천식 및 COPD와 같은 호흡기 질환의 전 세계 유병률 증가에 의해 주도되고 있습니다. 예를 들어 2023년 3월 16일 세계보건기구(WHO)에 따르면 만성폐쇄성폐질환(COPD)은 세계 3위의 사망원인이며, 2021년에는 3억 명 이상이 천식으로 고통받고, 매년 300만 명 이상이 COPD로 사망할 것으로 예상했습니다. 오염 수준 증가와 생활습관의 변화는 폐 질환의 발병률 증가에 기여하고 있습니다. 이 시장은 또한 호흡기에 직접적으로 영향을 미치는 질환을 치료하는 데 있으며, 흡입 가능한 약물의 우수한 치료 효과의 혜택을 누리고 있습니다. 정량적 흡입기(MDI)와 건조 분말 흡입기(DPI)와 같은 약물전달 장비의 기술 발전은 새로운 치료 기회를 확대하고 있습니다. 그러나 흡입 가능한 약물의 개발 및 생산과 관련된 높은 비용은 더 넓은 시장의 성장을 제한하고 있습니다. 또한 폐 약물전달 시스템의 임상시험 및 제품 승인에 대한 엄격한 규제 역시 제약 요인으로 작용하고 있습니다. 그럼에도 불구하고 첨단 제형 및 병용 요법에 대한 연구개발이 진행 중이기 때문에 예측 기간 중 새로운 길이 열릴 수 있습니다.
본 조사의 주요 특징
- 세계의 흡입 가능 약제 시장을 상세 분석하고 2022년을 기준년으로 한 예측 기간(2023-2030년)의 시장 규모와 연평균 성장률(CAGR %)을 제공합니다.
- 또한 다양한 부문에 걸친 잠재적 매출 기회를 설명하고, 이 시장에 대한 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 주요 인사이트도 제공하고 있습니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터에 기반하여 세계의 흡입 가능 약제 시장의 주요 기업을 프로파일링하고 있습니다.
- 이 리포트로부터 인사이트는 마케팅 담당자 및 기업의 경영진이 향후 제품의 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 기반한 의사결정을 시행하는 것을 가능하게 합니다.
- 세계의 흡입약 시장 리포트는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참여업체, 재무 애널리스트 등 이 업계의 다양한 이해관계자에게 대응하고 있습니다.
- 이해관계자는 세계의 흡입 가능한 약제 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 리포트 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 규제 시나리오
- PEST 분석
- Porter의 산업 분석
- 합병, 인수, 협업
제4장 세계의 흡입약 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- 신종 코로나바이러스 감염증(COVID-19)의 역학
- 공급측과 수요측 분석
- 경제적 영향
제5장 세계의 흡입약 시장, 약제 클래스별, 2018-2030년
- 서론
- 흡입 코르티코스테로이드
- 류코트리엔 수식제
- 장시간 작용형 β길항제(LABA)
- 장시간 작용형 무스카린 길항제(LAMA)
- 기타
제6장 세계의 흡입약 시장, 제품 유형별, 2018-2030년
제7장 세계의 흡입약 시장, 용도별, 2018-2030년
- 서론
- 호흡기질환
- 천식
- 만성폐쇄성폐질환(COPD)
- 낭포성섬유증
- 알레르기성 비염
- 기타
- 비호흡기질환
제8장 세계의 흡입약 시장, 유통 채널별, 2018-2030년
제9장 세계의 흡입약 시장, 지역별, 2018-2030년
- 서론
- 북미
- 미국
- 캐나다
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN 국가
- 기타 아시아태평양
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 북아프리카
- 중앙아프리카
- 남아프리카
제10장 경쟁 구도
- 기업 개요
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck &Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
제11장 섹션
KSA
영문 목차
Global inhalable drugs market size is expected to reach US$ 56.68 Bn by 2030, from US$ 34.86 Bn in 2023, exhibiting a CAGR of 7.2% during the forecast period.
| Report Coverage |
Report Details |
| Base Year: |
2022 |
Market Size in 2023/2024: |
US$ 34.86 Bn |
| Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: |
7.20% |
2030/2031 Value Projection: |
US$ 56.68 Bn |
Figure 1. Global Inhalable Drugs Market Share (%), By Region, 2023
Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.
Market Dynamics:
Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global inhalable drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market
Detailed Segmentation:
- Global Inhalable Drugs Market, By Drug Class
- Inhaled Corticosteroids
- Leukotriene modifiers
- Long-acting beta agonists (LABAs)
- Long-acting muscarinic antagonists (LAMAs)
- Others
- Global Inhalable Drugs Market, By Product Type
- Aerosol
- Dry powder Formulation
- Spray
- Others
- Global Inhalable Drugs Market, By Application
- Respiratory Diseases
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Global Inhalable Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Inhalable Drugs Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Top Companies in the Global Inhalable Drugs Market:
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Inhalable Drugs Market, By Drug Class
- Global Inhalable Drugs Market, By Product Type
- Global Inhalable Drugs Market, By Application
- Global Inhalable Drugs Market, By Distribution Channel
- Global Inhalable Drugs Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing prevalence of respiratory diseases
- Risk of misuse of inhalable medicines
- Emergence of new drug delivery technologies
- Key Highlights
- Regulatory Scenario
- Recent Trends
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Inhalable Drugs Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Inhalable Drugs Market, By Drug Class, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Inhaled Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Leukotriene modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Long-acting beta antagonists (LABAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Long-acting muscarinic antagonists (LAMAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
6. Global Inhalable Drugs Market, By Product Type, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Dry powder Formulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
7. Global Inhalable Drugs Market, By Application, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
8. Global Inhalable Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
9. Global Inhalable Drugs Market, By Region, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019 -2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
- Analyst Views
11. Section
- Reference
- Research Methodology
- About us
관련자료
